EXEMESTANE (ex-e-mes'tain) Aromasin Classifications: antineoplastic; aromatase inhibitor, steroidal; antiestrogen; Therapeutic: antineoplastic; steroidal aromatase inhibitor Prototype: Anastrozole Pregnancy Category: D |
25 mg tablet
Steroidal aromatase inhibitor that suppresses plasma estrogens estradiol and estrone without affecting cortisol or aldosterone synthesis in the adrenal glands. The enzyme, aromatase converts estrone to estradiol.
Breast tumor regression is possible in postmenopausal women. Effectiveness is indicated by evidence of tumor regression.
Estrogen-receptor positive early breast cancer following treatment with tamoxifen, treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Hypersensitivity to exemestane; pregnancy (category D), lactation. Safety and efficay in children not established.
Hepatic or renal insufficiency; GI disorders; cardiovascular disease; hyperlipidemia.
Early and Advanced Breast Cancer Adult: PO 25 mg q.d. after a meal |
Assessment & Drug Effects
Patient & Family Education